MA31356B1 - Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux - Google Patents

Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux

Info

Publication number
MA31356B1
MA31356B1 MA32315A MA32315A MA31356B1 MA 31356 B1 MA31356 B1 MA 31356B1 MA 32315 A MA32315 A MA 32315A MA 32315 A MA32315 A MA 32315A MA 31356 B1 MA31356 B1 MA 31356B1
Authority
MA
Morocco
Prior art keywords
treatment
gastrointestinal cancers
hdac inhibitors
relates
hdac
Prior art date
Application number
MA32315A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39683987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31356(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31356B1 publication Critical patent/MA31356B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'un inhibiteur de la hdac pour préparer un médicament destiné au traitement des cancers gastro-intestinaux. L'invention concerne également un procédé de traitement d'un animal à sang chaud, en particulier un être humain, ayant un cancer gastro-intestinal, ledit procédé comprenant l'administration audit animal d'une quantité thérapeutiquement efficace d'un inhibiteur de la hdac, en particulier un composé de formule (i) tel que défini ici. L'invention concerne en outre une composition pharmaceutique et un emballage commercial.
MA32315A 2007-05-04 2009-10-30 Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux MA31356B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91599607P 2007-05-04 2007-05-04
PCT/US2008/062341 WO2008137630A1 (fr) 2007-05-04 2008-05-02 Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux

Publications (1)

Publication Number Publication Date
MA31356B1 true MA31356B1 (fr) 2010-05-03

Family

ID=39683987

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32315A MA31356B1 (fr) 2007-05-04 2009-10-30 Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux

Country Status (16)

Country Link
EP (1) EP2142190A1 (fr)
JP (1) JP2010526149A (fr)
KR (1) KR20100016171A (fr)
CN (1) CN101674825A (fr)
AU (1) AU2008247603A1 (fr)
BR (1) BRPI0811112A2 (fr)
CA (1) CA2683554A1 (fr)
CL (1) CL2008001269A1 (fr)
IL (1) IL201318A0 (fr)
MA (1) MA31356B1 (fr)
MX (1) MX2009011692A (fr)
RU (1) RU2009144842A (fr)
TN (1) TN2009000427A1 (fr)
TW (1) TW200908964A (fr)
WO (1) WO2008137630A1 (fr)
ZA (1) ZA200906739B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603123B (zh) * 2023-11-04 2026-03-13 郑州大学 新型吲哚类hdac6小分子抑制剂、制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20070167499A1 (en) * 2003-10-27 2007-07-19 A*Bio Pte Ltd. Biaryl linked hydroxamates: preparation and pharmaceutical applications
CA2543570A1 (fr) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Hydroxamates connectes a l'acyluree et a la sulfonyluree
WO2006075165A1 (fr) * 2005-01-13 2006-07-20 Btg International Limited Combinaison de virus oncolytiques a des inhibiteurs d'angiogenese

Also Published As

Publication number Publication date
TW200908964A (en) 2009-03-01
AU2008247603A1 (en) 2008-11-13
WO2008137630A1 (fr) 2008-11-13
EP2142190A1 (fr) 2010-01-13
IL201318A0 (en) 2010-05-31
MX2009011692A (es) 2009-11-10
BRPI0811112A2 (pt) 2014-12-23
JP2010526149A (ja) 2010-07-29
TN2009000427A1 (en) 2011-03-31
RU2009144842A (ru) 2011-06-10
ZA200906739B (en) 2010-06-30
CL2008001269A1 (es) 2008-12-19
KR20100016171A (ko) 2010-02-12
CA2683554A1 (fr) 2008-11-13
CN101674825A (zh) 2010-03-17

Similar Documents

Publication Publication Date Title
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
MA32225B1 (fr) Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
MA34474B1 (fr) Agonistes de gpr40
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
NO20043367L (no) Oralt farmasoytisk preparat
MA29543B1 (fr) Procedes pour traiter un cancer pharmacoresistant
MA33923B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MA35363B1 (fr) Utilisation d'un composé organisation dans le traitement du syndrome de noonan
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2010002192A (es) Compuesto de tetrahidroquinolina que antagonizan el receptor tsh.
MA31356B1 (fr) Utilisation d'inhibiteurs de la hdac pour le traitement des cancers gastro-intestinaux
EA200500045A1 (ru) Новые соединения, их применение и получение